Meningococcal vaccines in Canada: An update

Paediatrics and Child Health

Volumn 16, Issue 8, 2011, Pages 485-486

  Salvadori, M I ^a   Bortolussi, R ^a   Finlay, Jane C ^a   Martin, Susanna ^a   McDonald, Jane C ^a   Onyett, Heather ^a   Robinson, Joan L ^a  

^a NONE

Author keywords

Adolescents, children, canada; MCV 4; Meningococcal infection; Meningococcal vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; W 135;

CANADA; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC MENINGITIS; HEALTH CARE PERSONNEL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; SHORT SURVEY; VACCINATION;

EID: 80053913544     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.8.485     Document Type: Short Survey

References (9)

1. Embree J; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Meningococcal vaccine for children. Paediatr Child Health 2002;7(6):425-6.
2. Bortolussi R, Salvadori M; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. A new meningococcal conjugate vaccine: What should physicians know and do? Paediatr Child Health 2009;14(8):515-20.
3. MacDonald NE, Bortolussi R; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. A harmonized immunization schedule for Canada: A call to action. Paediatr Child Health 2011;16(1):29-31.
4. Public Health Agency of Canada, National Advisory Committee on Immunization (NACI). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. CCDR 2009;35(ACS-3):2-36. 〈http://origin.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-3/ index-eng.php〉 (Accessed on August 4, 2011).
5. Public Health Agency of Canada. Publicly funded immunization programs in Canada - Routine schedule for infants and children including special programs and catch-up programs (as of March 2011). 〈http://www.phac-aspc.gc.ca/im/ ptimprog-progimpt/table-1-e.html〉 (Accessed on August 4, 2011).
6. Public Health Agency of Canada. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. CCDR 2007;33:1-15. 〈http://www.phacaspc.gc.ca/publicat/ccdr-rmtc/07vol33/ dr3310a-eng.php〉 (Accessed on August 4, 2011).
7. Canadian Immunization Monitoring Program, Active (IMPACT); Bettinger JA, Scheifele DW, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28(3):220-4.
8. Le Saux N, Bettinger JA, Wootton S, et al. Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol 2009;20(4):e130-4.
9. De Wals P, Nguyen VH, Erikson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004;22(9-10):1233-40. (Pubitemid 38296667)